We also noted that anti-CD47 when combined with olaparib downregulated immunosuppressive myeloid markers in cancer cells specifically, TGFBR1 and CSF1R, which has been shown to correlate with therapy resistance (Fig. 4C). This evidence concerns the gene CSF1R and cancer.